Shire Regulatory News (SHP)

Results of the Annual General Meeting held on April 24, 2012

Dublin, Ireland - April 24, 2012 - Shire plc , the global specialty biopharmaceutical company (the "Company") announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

For* % Against % Withheld Total % of
** votes relevant
validly shares
cast in issue
†

1. To receive the 418,002,081 99.53 1,976,774 0.47 148,326 419,978,855 74.66

Company's
accounts
together with
the reports of
the Directors
and Auditor

2. To approve the 411,583,191 98.39 6,730,515 1.61 1,813,475 418,313,706 74.36

Directors'
remuneration
report

3. To re-elect 419,093,911 99.80 850,198 0.20 183,072 419,944,109 74.65

William Burns
as a Director
of the Company

4. To re-elect 398,450,620 95.32 19,569,781 4.68 2,106,780 418,020,401 74.31

Matthew Emmens
as a Director
of the Company

5. To re-elect 419,160,380 99.81 783,870 0.19 182,931 419,944,250 74.65

Dr. David
Ginsburg as a
Director of
the Company

6. To re-elect 419,789,314 99.96 153,128 0.04 184,739 419,942,442 74.65

Graham
Hetherington
as a Director
of the Company

7. To re-elect 419,860,547 99.98 80,764 0.02 185,870 419,941,311 74.65

David Kappler
as a Director
of the Company

8. To re-elect 419,851,750 99.98 91,564 0.02 183,867 419,943,314 74.65

Anne Minto as
a Director of
the Company

9. To re-elect 419,854,943 99.98 84,052 0.02 188,186 419,938,995 74.65

Angus Russell
as a Director
of the Company

10. To re-elect 419,139,038 99.81 804,195 0.19 183,948 419,943,233 74.65

David Stout as
a Director of
the Company

11. To elect Susan 419,858,255 99.98 83,492 0.02 185,434 419,941,747 74.65

Kilsby as a
Director of
the Company

12. To re-appoint 419,580,038 99.91 382,738 0.09 164,405 419,962,776 74.66

Deloitte LLP
as Auditor of
the Company

13. To authorize 419,952,105 99.99 35,533 0.01 139,543 419,987,638 74.66

the Audit,
Compliance &
Risk Committee
to determine
the
remuneration
of the Auditor

14. To authorize 378,250,630 91.29 36,074,487 8.71 5,802,064 414,325,117 73.65

the allotment
of shares

15. To authorize 411,936,691 98.41 6,655,573 1.59 1,534,917 418,592,264 74.41

the
disapplication
of pre-emption
rights

16. To authorize 419,037,905 99.80 840,219 0.20 249,057 419,878,124 74.64
market
purchases

17. To approve the 367,519,055 87.51 52,460,162 12.49 147,964 419,979,217 74.66

reduced notice
period for
general
meetings

* These figures include discretionary votes

** A vote "withheld" is not a vote in law and is not counted in the calculation of the proportion of votes validly cast

†As at the record date, April 22, 2012, there were 562,532,330 ordinary shares in issue. Shareholders are entitled to one vote per share.

In accordance with Listing Rule 9.6.2 copies of the relevant resolution passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.hemscott/nsm.do.

For further information please contact:

Investor Relations

Eric Rojas erojas@shire.com +1 781 482 0999

Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157

Media

Jessica Mann (Corporate) jmann@shire.com +44 1256 894 280
Notes to editors
SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

1